Thermo Fisher Scientific Reaches New 52-Week High (TMO)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Thermo Fisher Scientific (NYSE: TMO) hit a new 52-week high Friday as it is currently trading at $61.32, above its previous 52-week high of $61 with 280,459 shares traded as of 10:01 a.m. ET. Average volume has been 1.9 million shares over the past 30 days.

Thermo Fisher Scientific has a market cap of $21.84 billion and is part of the health care sector and health services industry. Shares are up 32.9% year to date as of the close of trading on Thursday.

Thermo Fisher Scientific, Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. The company has a P/E ratio of 19.9, equal to the average health services industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, attractive valuation levels, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Thermo Fisher Scientific Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Jim Cramer: Agilent Technology Has Been One of My Favorites

Secondaries Get Primary Attention; Discerning Market -- Cramer's Top Thoughts

Cramer: Secondary Offerings Get Primary Attention

The Stock Market Is on Fire, Especially in These Sectors: Market Recon

PerkinElmer Among Targets Fitting Thermo Fisher's M&A Criteria